An Open-Label, Dose Escalation Phase I Trial of MK0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers
Trial Duration of Treatment : Patients will receive study drug for about 12 weeks. Patients
may be able to receive MK0646 for as long as 1 year if it seems to be stopping the growth of
their cancer and not causing bad side effects. If the patient has a complete response to
MK0646, you can have up to 8 additional weeks of treatment.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Blood concentrations of study drug; dose limiting toxicity (DLT)
After first dose; prior to next dose of study drug
No
Medical Monitor
Study Director
Merck
United States: Food and Drug Administration
2008_511
NCT00635778
August 2006
November 2008
Name | Location |
---|